The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
Source: The HillRead the full story at The Hill →
Subscribe to get our latest news, updates, and offers delivered straight to your inbox.
No spam, ever. Unsubscribe at any time.
Thanks for joining. Check your inbox to confirm your subscription.